Immunotherapy drug helps patients go cancer-free for twice as long, trial shows
Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care.
It also slashed the risk of the disease returning in another part of the body, the study suggests.
Head and neck cancer refers to a group of cancers that can develop anywhere in the head or neck, including the mouth, the oesophagus, the space behind the nose, the salivary gland, or the voice box.
Standard care, which includes surgery to remove tumours followed by radiotherapy with or without chemotherapy, has not changed for these patients in more than two decades, according to researchers.
The global Keynote-689 trial was carried out at 192 sites in 24 countries, and involved 714 patients.
Some 363 people received pembrolizumab followed by standard care, with the remainder receiving standard care only.
Pembrolizumab works by targeting a protein known as PD-L1, which is found on T cells and helps the immune system recognise and fight cancer.
By blocking this protein, the treatment helps the immune system fight cancer more effectively.
The treatment is already approved for use on its own or in combination with chemotherapy for patients with a certain type of head and neck cancer that has come back or spread around the body.
The trial, which is being presented at the American Society of Clinical Oncology (Asco) annual meeting, found cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care.
After three years, the risk of cancer returning somewhere else in the body was also 10% lower among those on pembrolizumab.
Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades.
'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas.
'This research shows that immunotherapy could change the world for these patients – it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.'
Prof Harrington added that the drug 'dramatically increases the duration of disease remission – for years longer than the current standard treatments'.
'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said.
It is estimated there are about 12,800 cases of head and neck cancer in the UK each year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
3 days ago
- Reuters
Merck extends pause on China Gardasil shipments to year end, shares slip
July 29 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to persistent weakness in demand for the blockbuster human papillomavirus vaccine, sending its shares down as much as 8%. The drugmaker, which reported lower second-quarter results, had previously said the pause would last at least until the middle of this year. It had suspended the shipments in February. Gardasil has been one of Merck's top growth drivers aside from blockbuster cancer immunotherapy Keytruda, and much of its international growth has come from China. Softer Gardasil demand in Japan also hurt Merck's sales, and the region is expected to be a "more significant headwind" in the back half of the year. "The Gardasil pain looks like it might drift into 2026 - credibility for management on this topic is still a sore point," said Bernstein analyst Courtney Breen. Merck CFO Caroline Litchfield tried to reassure investors and said that "Gardasil China represents a fraction of our company now, much less than 1%, we're not counting on it for growth." The company on Tuesday also announced job and cost cuts that it said will save $3 billion annually by the end of 2027, and kept its outlook for tariff-related costs unchanged at $200 million, pending any additional potential government actions. The cost cuts include $1.7 billion in annual savings from the elimination of certain administrative, sales and R&D positions, Merck said. It also plans to reduce its global real estate footprint and optimize its manufacturing network. "We are looking to reallocate money and resources from the slower growth areas of the business to fully fund fast-growing areas of our business," CEO Rob Davis said on the second-quarter earnings call. The company is focusing on newer drugs, including lung disease treatments Winrevair and Ohtuvayre, which was recently acquired in a $10 billion takeover of UK-based Verona Pharma. Investors have, however, been concerned about how Merck would replace revenue from Keytruda, the world's best-selling drug, which is set to lose patent protection toward the end of the decade. Declining sales of Gadrasil have added to Merck's pain. Shares of the company have lost more than 36% of their value since Merck first flagged weakness in China sales of the vaccine last year. Second-quarter sales of Gadrasil missed Wall Street's lowered estimates, according to data compiled by LSEG. Merck sold $1.1 billion of the vaccine, down 55% from a year ago. The acquisition of Verona "was a good first step, but investors want to see further evidence, either through additional M&A or pipeline successes, that Merck can offset the coming decline in Keytruda sales," said James Harlow, senior vice president at Novare Capital Management. Merck earned $5.4 billion, or $2.13 a share, in the second quarter, down 7% from a year earlier. Analysts had forecast earnings of $2.01. Revenue in the quarter fell 2% to $15.8 billion, compared with analysts' estimate of $15.9 billion. The company now expects to earn $8.87 to $8.97 a share in 2025, above analysts' estimates of $8.87.
Telegraph
22-07-2025
- Telegraph
The new stage four cancer treatments and what they mean for patients
A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden's prostate cancer was recently labelled 'aggressive' and described as having spread to his bones, many assumed the worst. Yet today, thanks to astonishing advances in cancer science, a stage-four label need not mean imminent death. 'Stage four means the cancer has spread to another part of the body further away from where it started,' explains Dr Ben O'Leary, a clinical oncologist at the Royal Marsden and a researcher at The Institute of Cancer Research (ICR). 'Most stage-four cancers still can't be cured, but our deeper understanding of how cancers evolve and grow means many people are living longer. In some cases, we now see responses, and yes, even cures, that weren't thought possible 10 years ago.' What's driving this optimism? Five types of cancer offer a snapshot of progress. Skip to: Prostate cancer Blood cancers Breast cancer Bladder cancer Lung cancer Prostate cancer By the age of 80, half of men harbour cancer in their prostate, though it proves fatal in only a small minority. Even so, around 12,000 men die of metastatic prostate cancer each year in the UK. Dr Anna Wilkins of the ICR and Royal Marsden says metastatic prostate cancer most often spreads to the bones. 'On scans, you can see up to 50 spots all over the skeleton. But there has been big progress in new drugs.' Total testosterone blockade Standard treatment reduces testosterone, the hormone that fuels tumour growth. Abiraterone, developed at the ICR, goes further by blocking its precursor hormones, extending survival significantly. Liquid radiotherapy This exciting development involves injecting patients with a radioactive liquid. Cancer cells 'drink' more of the liquid than healthy cells and the resulting burst of radiation destroys bone metastases. Liquid radiotherapy drug Radium-223 is already available on the NHS, while the even more potent Lutetium-177 PSMA is available privately and awaiting National Institute of Health and Care Excellence (Nice) appraisal. Multimodal first strikes 'We now combine hormone drugs – and sometimes chemotherapy – immediately after diagnosis,' says Dr Wilkins. Even resistant cancers respond to this approach. Treating the original tumour with radiotherapy, even in metastatic cases, also boosts survival: 'It's as if you're silencing a mothership that coordinates the metastases,' she says. While there is no cure yet, Dr Wilkins says, these approaches are turning stage-four prostate cancer into a condition many men will live with, not die from.
The Independent
15-07-2025
- The Independent
The new technique that has ‘transformed' breast cancer treatment
A new, more targeted radiotherapy treatment for low-risk breast cancer has been adopted by the NHS, aiming to reduce debilitating side effects. The Import Low trial, involving over 2,000 women, demonstrated that limiting radiation to the tumour area is as effective as treating the whole breast in preventing cancer recurrence over a decade. Patients undergoing this partial-breast radiotherapy experienced significantly fewer side effects and changes in breast appearance compared to those receiving whole-breast treatment. Researchers from The Institute of Cancer Research and the University of Cambridge led the study, which has "transformed" the approach to early breast cancer treatment. This new method is now integrated into NHS treatment guidelines and informs international practices, with over 9,000 women in the UK potentially benefiting.
